Cardiovascular compositions and methods using combinations of anti-platelet agents

Abstract

A method and composition for inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general vascular therapeutic and diagnostic procedures. The composition preferably includes multiple pain and inflammation inhibitory agents and spasm inhibitory agents. Specific preferred embodiments of the solution of the present invention for use in cardiovascular and general vascular procedures also may include anti-restenosis agents.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]The present application is a continuation of U.S. patent application Ser. No. 11 / 805,705, filed May 24, 2007, which is a continuation of U.S. patent application Ser. No. 11 / 709,346, filed Feb. 20, 2007, which is a continuation of U.S. patent application Ser. No. 11 / 603,937, Filed Nov. 22, 2006, which is a continuation of U.S. patent application Ser. No. 11 / 519,434, filed Sep. 12, 2006, which is a continuation of U.S. patent application Ser. No. 11 / 486,394, filed Jul. 13, 2006, which is a continuation of U.S. patent application Ser. No. 11 / 412,704, filed Apr. 27, 2006, which is a continuation of U.S. patent application Ser. No. 11 / 355,314, filed Feb. 15, 2006, which is a continuation of U.S. patent application Ser. No. 11 / 270,335, filed Nov. 11, 2005, which is a continuation of U.S. patent application Ser. No. 11 / 197,136, filed Aug. 4, 2005, now abandoned, which is a continuation of U.S. patent application Ser. No. 11 / 119,347, filed Apr. 2...

AI Technical Summary

Benefits of technology

The present invention provides a solution for inhibiting pain, inflammation, spasm, and restenosis at a surgical site by delivering a mixture of multiple agents in low concentrations through a perioperative delivery method. This solution can be used in various surgical procedures to preemptively limit pain, inflammation, spasm, and restenosis at the site. The solution contains anti-pain / anti-inflammation agents, anti-spasm agents, and anti-restenosis agents, which act through different molecular mechanisms of action to inhibit pain, inflammation, spasm, and restenosis. The use of this solution provides a more effective and efficient way to manage pain and inflammation during surgery compared to other methods.

Problems solved by technology

Conventional physiologic irrigation fluids do not provide analgesic, anti-inflammatory, anti-spasm and anti-restenotic effects.

The high incidence of nausea and vomiting related to opioids is especially problematic in the postoperative period.

Therapeutic agents aimed at treating postoperative pain while avoiding detrimental side effects are not easily developed because the molecular targets for these agents are distributed widely throughout the body and mediate diverse physiological actions.

Despite the significant clinical need to inhibit pain and inflammation, as well as vasospasm, smooth muscle spasm and restenosis, methods for the delivery of inhibitors of pain, inflammation, spasm and restenosis at effective dosages while minimizing adverse systemic side effects have not been developed.

As an example, conventional (i.e., intravenous, oral, subcutaneous or intramuscular) methods of administration of opiates in therapeutic doses frequently is associated with significant adverse side effects, including severe respiratory depression, changes in mood, mental clouding, profound nausea and vomiting.

In addition, prostaglandins also are known to cause pain and inflammation.

Cyclooxygenase inhibitors are associated with some adverse systemic side effects when applied conventionally.

However, there are differences in pharmacology and receptor sequences between human and animal species.

Furthermore, antagonists of these mediators currently are not used for postoperative pain treatment.

Therefore, the lack of efficacy in reducing postoperative pain in the previously-mentioned studies would appear to conflict with the proposal of a role for endogenous 5-HT in acute pain.

With oral administration, the concentration of amitriptyline in the operative site tissues may not have been sufficiently high for a long enough time period to inhibit the activity of postoperatively released 5-HT in the second study.

(3) Since multiple inflammatory mediators exist, and studies have demonstrated synergism between the inflammatory mediators, blocking only one agent (5-HT) may not sufficiently inhibit the inflammatory response to tissue injury.

Images